摘要
目的评价依达拉奉联合银杏达莫注射液在缺血性患者治疗中的有效性及安全性。方法选取符合入选标准的72例血管性认知功能损害(VCI)患者,随机分为2组,常规对照组(34例)给予胞磷胆碱注射液静脉滴注,共14 d;联合治疗组(38例)在常规治疗基础上加用依达拉奉、银杏达莫注射液静脉滴注。比较2组治疗后简易精神状态量表(MMSE)评分变化及副反应,初步探讨蒙特利尔认知量表(MoCA)在筛查非痴呆性血管性认知障碍(VCIND)的作用。结果 VCI患者应用依达拉奉联合银杏达莫注射液治疗后MMSE评分与治疗前比较,差异有统计学意义(P<0.05),与对照组治疗后比较,差异也有统计学意义(P<0.05);副作用:轻度头昏、头胀痛或上腹不适感。结论依达拉奉联合银杏达莫治疗VCI患者安全有效,改善脑缺血产生的症状和记忆功能,MoCA显示出比MMSE更能识别出轻微的认知功能障碍。
Objective To evaluate the effect and safety of edaravone combined with Yinx- ingdamo injection in treating patients with vascular cognitive impairment. Methods Seventy-two patients with vascular cognitive impairment （VCI） were enrolled and divided randomly into two groups. The control group （n = 32） received citicoline injection for two weeks and the treatment group （n = 40） received edaravone combined with Yinxingdamo injection in addition to the treat- ment for the control group. The changes of mini-mental state examination （MMSE） score and side effects, preliminary study of the effect of Montreal Cognitive Scale （MoCA） in the screening of vas- cular cognitive impairment no dementia （VCIND） were compared. Results Compared with the control group, VCI patients who received edaravone in combination of Yinxingdamo injection showed significant differences of MMSE score after treatment （ P 〈 0.05）, and the difference was statistically significant （P 〈 0.05）. Side effects included mild dizziness, head pain or abdominal discomfort. Conclusion Edaravone combined with Yinxingdamo injection is safe and effective for treatment of VCI. MoCAm is better than the MMSE to identify mild cognitive impairment.
出处
《实用临床医药杂志》
CAS
2012年第21期115-117,共3页
Journal of Clinical Medicine in Practice
